Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8<sup>+</sup> T cells and reprogramming macrophages.
Tichet M., Wullschleger S., Chryplewicz A., Fournier N., Marcone R., Kauzlaric A., Homicsko K., Deak L.C., Umaña P., Klein C. et al., 2023/01/10. Immunity, 56 (1) pp. 162-179.e6. Peer-reviewed.
ici le détail